by Richard Daverman, PhD
April 23, 2013 -- A subsidiary of Hua Han Bio-Pharmaceutical Holdings, Guizhou Factorr Bio-Technology, signed a framework agreement to set up a JV with National Vaccine & Serum Institute. NVSI is a Beijing-based company that is part of the China National Biotec Group. Guizhou will fund the JV with between 30 and 50 million RMB of capital ($5-8 million), while NVSI will contribute rights to three biopharma products. More details....
Stock Symbol: (HK: 00587)
